Navigation Links
Novavax Announces Board of Director Changes
Date:10/1/2009

milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, initiation, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; regulatory approval is needed before any vaccines can be sold in or outside the US; the rate and progress of manufacturing scale-up; Novavax's pilot plant facility is subject to standard FDA inspections, which may result in increased costs and production delays; the success of the Company's joint ventures and licensing agreements; the Company's ability to enter into future collaborations with industry partners and governments and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; the Company's ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; the Company's ability to obtain adequate financing in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, fina
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
2. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
3. Novavax Reports Second Quarter 2009 Financial Results
4. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
5. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
6. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
7. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
8. Novavax Announces Repayment of $5 Million of Convertible Debt
9. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
10. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
11. Novavax Appoints Stanley Erck to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... Triangle Park, NC (PRWEB) January 14, 2014 ... company focusing on ultra-sensitive POC diagnostic platforms and novel disease ... their first round of financing netting a total of $690,000. ... outside equity capital in the company. This group of private ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Focus on Critical Industry Issues -- DUBAI, UAE, September 8, 2010 ... ... ... keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... YORK, Sept. 7 Reportlinker.com announces that a ... catalogue: Biotechnology Pharmaceutical Market in ... Biotechnology Pharmaceutical Market in US ... Pharmaceutical market to grow at a CAGR of ...
... Inc. (OTC Bulletin Board: FCSC ), a ... therapies for aesthetic, medical and scientific applications, announced today ... to its scientific advisory board. In addition to being ... a biotechnology and genetic research expert. Dr. Gruenwald also ...
Cached Biology Technology:Cold Chain MENA 2010 to Focus on Critical Industry Issues 2Cold Chain MENA 2010 to Focus on Critical Industry Issues 3Cold Chain MENA 2010 to Focus on Critical Industry Issues 4Cold Chain MENA 2010 to Focus on Critical Industry Issues 5Cold Chain MENA 2010 to Focus on Critical Industry Issues 6Reportlinker Adds Biotechnology Pharmaceutical Market in US -2013 2Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board 2Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board 3
(Date:4/23/2014)... TX (4/23/14) -- Researchers have found evidence of ... factors that increase aggressive behavior in children, especially ... not all children exposed to prenatal smoking will ... will not," said Brian Boutwell, Assistant Professor at ... and senior author on the study. "One ...
(Date:4/23/2014)... away from using triclosan as an antimicrobial ingredient in ... now scientists are reporting new evidence that appears to ... journal Chemical Research in Toxicology , found that ... promoted the growth of human breast cancer cells in ... Kyung-Chul Choi and colleagues note that hormonal imbalances seem ...
(Date:4/23/2014)... comprehensive study to date of the family of ... effective vaccine strategies and reveals surprising findings about ... could alter public health strategies to control this ... year. , Genomic analysis of 343 strains of ... the world collected over the last 100 years ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2
... Scheduling more physical education time in schools does not ... research that discovered those who got lots of timetabled ... while those who got little at school made up ... The scientists, who presented their research Thursday at the ...
... Inc. (Nasdaq: AWRE ), a leading supplier of ... its first quarter ended March 31, 2009. Revenues for ... of 22% compared to $5.9 million in the same quarter ... and diluted net income per share in accordance with U.S. ...
... Desert environments are characterized by poor vegetative cover, ... conditions. In this context, the land resources of ... are subjected to various land degradation stresses, including ... sustain the land resources of Abu Dhabi Emirate, ...
Cached Biology News:Study finds children's activity levels not influenced by more PE time in school 2Aware, Inc. Reports First Quarter 2009 Financial Results 2Aware, Inc. Reports First Quarter 2009 Financial Results 3Aware, Inc. Reports First Quarter 2009 Financial Results 4Aware, Inc. Reports First Quarter 2009 Financial Results 5Aware, Inc. Reports First Quarter 2009 Financial Results 6Wind, salt and water are leading indicators of land degradation in Abu Dhabi 2
...
Human Cystatin A MAb (Clone 224705)...
Corticoliberin...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Biology Products: